Clinical Trials
144 trialsTrial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC
University of California, San Diego
EACH
University College, London
CACTUX
Washington University School of Medicine
LYSARI
Centre Leon Berard
Pilot Study of Imatinib Cetuximab Combo for H & N Cancer
University of Wisconsin, Madison
Invert-Prospective Phase II Randomized Trial of Involved Nodal Versus Elective Neck RadioTherapy
University of Texas Southwestern Medical Center
A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer
Memorial Sloan Kettering Cancer Center
DARTBOARD
University of Texas Southwestern Medical Center
INTERLINK-1
AstraZeneca
Cisplatin With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Eastern Cooperative Oncology Group
PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
Dana-Farber Cancer Institute
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Tizona Therapeutics, Inc
Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
University of California, San Diego
Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer
Radiation Therapy Oncology Group
RT With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer
Radiation Therapy Oncology Group
Head and Neck Cancer Study Project in the Geriatric Population
Brown University
Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma
M.D. Anderson Cancer Center
Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)
Incyte Corporation
Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC
University of Chicago
Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies
Pfizer
AACER
Centre Antoine Lacassagne
A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
BioAtla, Inc.
Torisel in Addition to Standard Chemotherapy With Radiation for Advanced Head and Neck Cancer
Thomas Jefferson University
ECHO-07
GERCOR - Multidisciplinary Oncology Cooperative Group
MK-3475-048
Merck Sharp & Dohme LLC
NIVOTAX
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma
Memorial Sloan Kettering Cancer Center
REACH
Groupe Oncologie Radiotherapie Tete et Cou
AVEC-119
Gruppo Oncologico del Nord-Ovest
APA
Washington University School of Medicine
Induction Chemotherapy Followed by Chemoradiation With Cetuximab in Head and Neck Cancer
Institute of Oncology Ljubljana
Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma
University of Arizona
Palbociclib With Cetuximab and IMRT for Locally Advanced Squamous Cell Carcinoma
Mahidol University
Post-operative Radiation With Cetuximab for Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck
University of Cincinnati
Bevacizumab/Ph 2 for Locally Advanced Head and Neck Cancer
The University of Texas Health Science Center at San Antonio
ASOG-HNO1
Austrian South Oncology Group
Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Stanford University
Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
University of Cincinnati
V-CHANCE
National Cancer Institute, Naples
Penpulimab in Combination With Cetuximab as First-line Treatment in R/M SCCHN
Eye & ENT Hospital of Fudan University
CheckMate 651
Bristol-Myers Squibb
FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Fate Therapeutics
Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer
Pfizer
Cetuximab, Chemotherapy, and Radiation Therapy for Operable Stage III or IV Head and Neck Cancer
Eastern Cooperative Oncology Group
Phase II Study of Concurrent C225, Cisplatin and Radiation in Stage IV Squamous Cell Carcinoma of the Head and Neck
Eastern Cooperative Oncology Group
Induction Chemotherapy Followed By Cetuximab and Radiation in HPV-Associated Resectable Stage III/IV Oropharynx Cancer
Eastern Cooperative Oncology Group
SBRT With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated SCCHN
University of Pittsburgh
Cetuximab in Head and Neck Cancer Patients
University of Wisconsin, Madison
Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Innate Pharma
A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)
Hoffmann-La Roche